WSJ: Altman's Personal Investment Portfolio Forms Web of Interests with OpenAI Deals
Alina Collins
A WSJ investigation found that Altman personally holds stakes in over 80 startups, at least 10 of which have business ties with OpenAI — as the company prepares to go public, this web of interests is drawing congressional probes and calls for SEC scrutiny.
What does this web of interests look like?
Altman holds no direct equity in OpenAI — his income is not tied to the company's performance. But he personally invested in over 80 startups, at least 10 of which already have or are negotiating deals with OpenAI.
This means → he doesn't profit from OpenAI "on the inside," but may benefit through his portfolio companies "on the outside." Every partnership OpenAI signs could lift his personal holdings.
In plain terms = the money doesn't come through the front door, but it may come through the back. This structure is harder to track and regulate than straightforward equity ownership.
Helion — where is the biggest controversy?
Altman invested in fusion startup Helion in 2015 and became board chair. In 2021 he added $375 million — his largest single bet on any company.
In 2024, OpenAI signed a non-binding power-purchase agreement with Helion. Former board member Shivon Zilis testified the deal was "completely unexpected" because fusion remains a speculative technology.
This means → OpenAI committed to buying power from an unproven technology, and the biggest beneficiary happened to be the CEO's own portfolio company — the core of the self-dealing concern.
What did Altman do next?
In 2025, after helping broker SoftBank's investment in OpenAI, Altman steered SoftBank toward investing in Helion too. He then proposed that OpenAI invest roughly $500 million directly in Helion — the company refused.
In March 2026, OpenAI signed a revised deal with Helion; Altman stepped down from Helion's board the same month. By June, Helion raised a new round at a $15.5 billion valuation, with OpenAI backer Thrive Capital among the investors.
This reflects a clear value chain: Altman's personal stake more than doubled, reaching at least $4.1 billion.
Which other companies followed the same pattern?
Chips: Altman has held Cerebras shares for nearly a decade. OpenAI recently signed a chip-procurement deal with Cerebras, fueling a high-profile IPO — Altman's stake grew more than sixfold from December 2025.
Biotech: OpenAI formed research partnerships with at least two Altman-backed companies. Longevity startup Retro Biosciences carried an equity value of $258 million as of December 2025, per trial evidence in the Musk–OpenAI lawsuit.
In plain terms = Helion is not unique. Chips, biotech — wherever OpenAI signs a deal, Altman's personal ledger rises with it.
What do regulators think? Will the IPO be affected?
The U.S. House Oversight Committee has opened an inquiry into Altman's potential conflicts. Several state attorneys general have called on the SEC to intervene.
OpenAI board chair Bret Taylor says Altman has been "transparent" about disclosures and that the company has rigorous governance controls.
This means → public companies typically bar executives from holding large stakes in outside partners. How this "no equity but outside gains" structure is disclosed in the IPO prospectus will be the defining governance question before OpenAI lists.
Content is for reference only, not financial advice.